
X
Type 2 diabetes research: fewer side effects from modified medication
https://pharmaphorum.com/news/diabetes-research-modified-medication/
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
Novo expects Victoza and semaglutide to gain momentum.
Novo hopes data will justify higher price compared with rival.
Cardioprotective effect occurred in patients independently of blood sugar control
If approved semaglutide could become set the standard for GLP-1 therapy